Article
Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion - 22 Dec 2020
Sánchez-Ibarra Héctor E, Reyes-Cortes Luisa M, López-Tavera Esteban, Luna-Aguirre Claudia M, Barrera-Saldaña Hugo A
Abstract excerpt
BACKGROUND: The presence of clinically relevant mutations in KRAS and NRAS genes determines the response of anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer (mCRC). The only quantitative polymerase chain reaction (qPCR)-based diagnostic tests approved by the Food and Drug Administration (FDA) screen merely for mutations in codons 12 and 13 of KRAS. OBJECTIVE: The objective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.